AstraZeneca Results Presentation Deck
87H4
EGFR
Oncology - R&D highlights
Establishing AstraZeneca portfolio of differentiated ADCs
FRa
CLDN18.2
GPRCSD
Five wholly owned ADCs already in the clinic
Clinical stage trials ongoing in lung, breast, haematology, GYN/GU and GI
B7H4
TOP1i
CMET
TOP1i
Fita
TOPII
CLDN18.2
MMAE
GPRC5D
MMAE
AZD8205
(B7H4)
DAR 8
AZD9592
(EGFR/CMET)
DAR 6
AZD5335
(FRA)
DAR 8
AZD0901
(CLDN18.2)
DAR 4
CEO Opening Remarks
LM-305
(GPRC5D)
DAR 4
PRECLINICAL PHASE I
Financial Results
PHASE II
PHASE III
INDICATIONS OF INTEREST
Breast, BTC, ovarian,
endometrial
NSCLC, HNSCC
Ovarian, lung
Oncology
Gastric, GEJ, pancreatic
Multiple myeloma
Best SOD change from baseline, %
BioPharmaceuticals
60
AZD0901
Promising efficacy in gastric / GEJ cancer
40
20
0
-20
-40
-60
-80
-100
Rare Disease
2.2 mg/kg
2.6 mg/kg
3.0 mg/kg
A unconfirmed response
BoR in gastric / GEJ cancer (IHC 2+, ≥20% TC)¹
Phase I dose escalation / expansion
Claudin 18.2-
MMAE
warhead
CEO Closing Remarks
BER8999RESS
EEEEEEEEE
ValCit
linker
THOM
Broader clinical development
programme in progress
1. Xu RH et al. Abstract 434420 presented at ASCO Virtual Plenary on 7 November 2023. ADC images for illustrative purposes only; actual drug positions may vary.
ADC = antibody drug conjugate; GYN = gynaecological; GU = genitourinary; Gl = gastrointestinal; B7H4 = B7 homolog 4; DAR= drug to antibody ratio; EGFR= epidermal growth factor receptor: CMET =mesenchymal-epithelial transition factor ; FRα = folate receptor
alpha; CLDN18.2 = claudin 18.2; CPRC5D = G-protein coupled receptor C family 5D; TOP1i = topoisomerase 1 inhibitor; MMAE = monomethyl auristatin E; BTC = biliary tract cancer; NSCLC = non-small cell lung cancer; HSNCC = head and neck squamous cell
19 carcinoma; GEJ = gastroesophageal junction; BoR = best overall response; IHC = immunohistochemistry; TC = tumour cell; CR = complete response; PR = partial response; SD = stable disease; PD = progressive disease; NE = not evaluable.
Collaboration partner: Keymed Biosciences (AZD0901).View entire presentation